AstraZeneca to stop developing Crohn’s disease drug

Date:

Share post:

British drugmaker AstraZeneca said on Thursday (June 1) it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis.

The company said the discontinuation was due to a delay in the drug’s development timeline, affected by global events and “the context of a competitive landscape”.

AstraZeneca regained the rights to brazikumab from Allergan in 2020 following U.S. drugmaker AbbVie’s $63 billion tie-up with Allergan.

AbbVie will stop funding the drug’s development, AstraZeneca said.

AbbVie’s Skyrizi also treats Crohn’s disease.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue June 2023

Related articles

A new Haleon report claims growth of pain in the past decade

Consumer health company Haleon, formerly known as GSK, claims that pain's emotional and life impact has grown by...

Viatris to divest some businesses for nearly £3 billion

Drugmaker Viatris said on Sunday (October 1) it had reached agreements to divest some of its businesses for...

Titan PMR set to unveil ‘Titanverse’, a one-stop-shop tech solution for pharmacy businesses

Bristol-based Titan PMR, a technology firm specialising in PMR systems for community pharmacies, is set to roll out...

Six Scotland-based pharmacists recognised at celebratory RPS event in Edinburgh

Six pharmacists based in Scotland were acknowledged by the profession this week during a celebratory event held at...